• Boundless Bio disclosed open-market purchases by 10% owner Kevin Tang, manager of Tang Capital Management.
• Tang Capital entities bought 286,333 common shares at weighted-average prices of $2.47 to $2.56.
• Indirect stake rose to 2,533,845 common shares held through limited partnerships.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178579-26-000008), on June 29, 2026, and is solely responsible for the information contained therein.